Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Mangoceuticals (MGRX) Other Operating Expenses (2023 - 2025)

Mangoceuticals' Other Operating Expenses history spans 3 years, with the latest figure at $7.3 million for Q3 2025.

  • For Q3 2025, Other Operating Expenses rose 453.0% year-over-year to $7.3 million; the TTM value through Sep 2025 reached $15.7 million, up 147.37%, while the annual FY2024 figure was $5.4 million, 15.47% down from the prior year.
  • Other Operating Expenses for Q3 2025 was $7.3 million at Mangoceuticals, up from $4.1 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $7.3 million in Q3 2025 and bottomed at $903710.0 in Q4 2024.
  • The 3-year median for Other Operating Expenses is $1.9 million (2023), against an average of $2.7 million.
  • The largest annual shift saw Other Operating Expenses plummeted 52.13% in 2024 before it soared 453.0% in 2025.
  • A 3-year view of Other Operating Expenses shows it stood at $1.9 million in 2023, then tumbled by 52.13% to $903710.0 in 2024, then surged by 705.84% to $7.3 million in 2025.
  • Per Business Quant, the three most recent readings for MGRX's Other Operating Expenses are $7.3 million (Q3 2025), $4.1 million (Q2 2025), and $3.4 million (Q1 2025).